<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02504463</url>
  </required_header>
  <id_info>
    <org_study_id>ALK33-B107</org_study_id>
    <nct_id>NCT02504463</nct_id>
  </id_info>
  <brief_title>A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers</brief_title>
  <official_title>A Single-Center, Open-Label Study to Evaluate the Absorption, Metabolism, and Excretion of Single Doses of [14c]-Samidorphan in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the pharmacokinetics (PK) of [14c]-samidorphan in healthy male
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC 0-t</measure>
    <time_frame>Up to 120 hours after each dose</time_frame>
    <description>Area under the concentration time curve of total radioactivity from time 0 to last observed concentration in blood and plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 120 hours after each dose</time_frame>
    <description>Maximum concentration of total radioactivity in blood and plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 120 hours after each dose</time_frame>
    <description>Time to maximum concentration of total radioactivity in blood and plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fe%0-t</measure>
    <time_frame>Up to 120 hours after each dose</time_frame>
    <description>Fraction of dose excreted in urine and feces</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability will be measured by the incidence of Adverse Events</measure>
    <time_frame>Up to 35 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Samidorphan IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Samidorphan solution for IV administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Samidorphan sublingual</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[14c]-Samidorphan for sublingual administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Samidorphan oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[14c]-Samidorphan for oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Samidorphan IV</intervention_name>
    <description>Single IV administration</description>
    <arm_group_label>Samidorphan IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14c]-Samidorphan sublingual</intervention_name>
    <description>Single sublingual administration containing radiolabel</description>
    <arm_group_label>Samidorphan sublingual</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14c]-Samidorphan oral</intervention_name>
    <description>Single oral administration containing radiolabel</description>
    <arm_group_label>Samidorphan oral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) of greater than/equal to 19 and less than/equal to 32 kg/m^2 at
             screening (minimum weight of 50.0 kg)

          -  Generally good health

          -  Subjects must agree to reduce the risk of a female partner becoming pregnant during
             the study and for 30 days after the last dose of the study drug by abstinence from
             heterosexual relationships or use of a reliable contraceptive method

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Clinically significant illness within 30 days

          -  History of alcohol or opioid dependence, or positive urine toxicological screen for
             marijuana, cocaine, amphetamines, opioids, barbiturates, and benzodiazepines

          -  History of oral or gastrointestinal disease

          -  Irregular bowel or bladder function

          -  History of allergy or hypersensitivity to opioid medications or opioid antagonists
             (eg, naltrexone, naloxone)

          -  Current or pending legal charges or probation that would interfere with study conduct

          -  Use of alcohol within 24 hours prior to admission or urine positive test for alcohol
             at screening or admission

          -  Tobacco or nicotine use within 90 days

          -  Anticipated need for prescription medicines during the study period

          -  Additional criteria may apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arielle Stanford, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes Medical Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <last_update_submitted>September 17, 2015</last_update_submitted>
  <last_update_submitted_qc>September 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alkermes</keyword>
  <keyword>Samidorphan</keyword>
  <keyword>ALKS 33</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

